4. Ratio of ORs from MTM and this review.
| Outcomes | OR (95%CI) | Ratio of ORs* | |
| MTM (direct + indirect comparisons) (Cipriani 2009) | Direct comparisons (This review) | ||
| Response | |||
| paroxetine | 0.96 (0.76 to 1.23) | 0.83 (0.51 to 1.34) | 1.16 |
| sertraline | 0.79 (0.61 to 1.01) | 1.21 (0.53 to 2.75) | 0.65 |
| fluoxetine | 0.98 (0.77 to 1.23) | 1.00 (0.62 to 1.61) | 0.98 |
| citalopram | 0.88 (0.68 to 1.16) | 0.90 (0.50 to 1.62) | 0.98 |
| milnacipran | 0.97 (0.68 to 1.37) | 0.57 (0.26 to 1.23) | 1.70 |
| venlafaxine | 0.77 (0.59 to 0.99) | 0.40 (0.18 to 0.92) | 1.93 |
| mirtazapine | 0.71 (0.55 to 0.92) | 0.88 (0.59 to 1.31) | 0.81 |
| Total dropout | |||
| paroxetine | 1.10 (0.84 to 1.47) | 1.08 (0.63 to 1.85)** | 1.02 |
| sertraline | 1.38 (1.03 to 1.89) | 1.46 (0.19 to 11.16)** | 0.95 |
| fluoxetine | 1.22 (0.93 to 1.61) | 1.17 (0.66 to 2.09)** | 1.04 |
| citalopram | 1.37 (1.01 to 1.85) | 1.42 (0.75 to 2.67) | 0.96 |
| milnacipran | 1.18 (0.76 to 1.75) | 1.22 (0.54 to 2.77)** | 0.97 |
| venlafaxine | 1.14 (0.86 to 1.54) | 2.29 (0.97 to 5.43) | 0.50 |
| mirtazapine | 1.18 (0.87 to 1.61) | 0.83 (0.52 to 1.33) | 1.42 |
| MTM, multiple‐treatments meta‐analysis; OR, odds ratio; CI, confidence interval; For response, ORs higher than 1 favor fluvoxamine. For total dropout, ORs lower than one favour fluvoxamine; * ORs of this review as reference; **Data from three comparisons (Ansseau 1991a, Ansseau 1991b, and Gonul 1999) were omitted because these 4‐week trials were not included in MTM (Cipriani 2009). | |||